FREMONT, CA: Magnesium Elektron, a manufacturer and supplier of magnesium alloys, and BIOTRONIK– a provider of medical devices and technology– announces the development of SynerMag bioresorbable magnesium alloys for cardiovascular application.
Both Magnesium Elektron and BIOTRONIK entered into a joint research and development program in 2006 and aimed to develop a bioresorbable magnesium coronary scaffold. This has resulted in the development of Elektron’s SynerMag 410 alloy system being used as the platform material in the BIOTRONIK Magnesium Scaffold. The BIOTRONIK magnesium scaffold is a clinically proven magnesium based bioresorbable scaffold.
The latest generation of BIOTRONIK’s magnesium scaffold was clinically evaluated in the BIOSOLVE II study, to qualify the scaffold for CE certification approval. The release of the data was published in the Lancet Journal.
The magnesium Elektron’s manufacturing and testing facility achieved the ISO 13485 approval in 2014 and ensures a class-leading production facility for the manufacturing of the BIOTRONIK magnesium scaffold.
“The joint collaboration between our two companies has been the key element in the advancement of this new platform technology,” says Graham Wardlow, Managing Director of Magnesium Elektron’s operations in the U.K. and involved in the BIOTRONIK program since 2006. “The demands of the application and its operating environment threw up many challenges, and we could not have achieved the advances in alloy technology if it were not for the commitment of everyone involved in the program and the outstanding technical feedback we received from BIOTRONIK on the performance of our materials. We look forward to the product launch of the BIOTRONIK Magnesium Scaffold and the advancement of the SynerMag® range of bioresorbable magnesium alloys into new medical fields.”